B
Bertron M. Groves
Researcher at Anschutz Medical Campus
Publications - 88
Citations - 13852
Bertron M. Groves is an academic researcher from Anschutz Medical Campus. The author has contributed to research in topics: Pulmonary hypertension & Blood pressure. The author has an hindex of 41, co-authored 88 publications receiving 13381 citations. Previous affiliations of Bertron M. Groves include University of Colorado Denver & Free University of Berlin.
Papers
More filters
Journal ArticleDOI
A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension
Robyn J. Barst,Lewis J. Rubin,Walker Long,Michael D. McGoon,Stuart Rich,David B. Badesch,Bertron M. Groves,Victor F. Tapson,Robert C. Bourge,Bruce H. Brundage,Spencer K. Koerner,David Langleben,Cesar A. Keller,Srinivas Murali,Barry F. Uretsky,Linda M. Clayton,Maria M. Jöbsis,Shelmer D. Blackburn,Denise Shortino,James W. Crow +19 more
TL;DR: As compared with conventional therapy, the continuous intravenous infusion of epoprostenol produced symptomatic and hemodynamic improvement, as well as improved survival in patients with severe primary pulmonary hypertension.
Journal ArticleDOI
Primary pulmonary hypertension: a national prospective study
Stuart Rich,D R Dantzker,S M Ayres,Edward H. Bergofsky,Bruce H. Brundage,Katherine M. Detre,Alfred P. Fishman,Roberta M. Goldring,Bertron M. Groves,Spencer K. Koerner +9 more
TL;DR: Although no deaths or sustained morbid events occurred during the diagnostic evaluation of the patients, the typically long interval from initial symptoms to diagnosis emphasizes the need to develop strategies to make the diagnosis earlier.
Journal ArticleDOI
An Imbalance between the Excretion of Thromboxane and Prostacyclin Metabolites in Pulmonary Hypertension
Brian W. Christman,Charles D. McPherson,John H. Newman,Gayle A. King,Gordon R. Bernard,Bertron M. Groves,James E. Loyd +6 more
TL;DR: An increase in the release of the vasoconstrictor thromboxane A2, suggesting the activation of platelets, occurs in both the primary and secondary forms of pulmonary hypertension.
Journal ArticleDOI
Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.
David B. Badesch,Victor F. Tapson,Michael D. McGoon,Bruce H. Brundage,Lewis J. Rubin,Fredrick M. Wigley,Stuart Rich,Robyn J. Barst,Pamela S. Barrett,Kenneth M. Kral,Maria M. Jöbsis,James E. Loyd,Srinivas Murali,Adaani E. Frost,Reda E. Girgis,Robert C. Bourge,David D. Ralph,C. Gregory Elliott,Nicholas S. Hill,David Langleben,Robert Schilz,Vallerie V. McLaughlin,Ivan M. Robbins,Bertron M. Groves,Shelley Shapiro,Thomas A. Medsger,Sean Gaine,Evelyn M. Horn,James C. Decker,Katharine Knobil +29 more
TL;DR: Continuous epoprostenol therapy improves exercise capacity and cardiopulmonary hemodynamics in patients with pulmonary hypertension due to the scleroderma spectrum of disease as discussed by the authors.
Annals of Internal Medicine Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease
David B. Badesch,Victor F. Tapson,Michael D. McGoon,Bruce H. Brundage,Lewis J. Rubin,Fredrick M. Wigley,Stuart Rich,Robyn J. Barst,Pamela S. Barrett,Kenneth M. Kral,James E. Loyd,Srinivas Murali,A. Frost,Reda E. Girgis,Robert C. Bourge,David D. Ralph,C. Gregory Elliott,Nicholas Hill,David Langleben,Robert J. Schilz,Vallerie V. McLaughlin,Ivan M. Robbins,Bertron M. Groves,Shelley M. Shapiro,Sean Gaine,Evelyn M. Horn,James C. Decker,Katharine Knobil +27 more
TL;DR: Results from a single-center, uncontrolled study suggest that long-term, continuously infused epoprostenol therapy can produce hemodynamic and symptomatic responses in patients with connective tissue disease who have severe pulmonary hypertension that is refractory to conventional medical therapy.